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Abstract
Plasmodium falciparum, the causative agent of the most severe form of malaria in humans invades erythrocytes using
multiple ligand-receptor interactions. The P. falciparum reticulocyte binding-like homologue proteins (PfRh or PfRBL) are
important for entry of the invasive merozoite form of the parasite into red blood cells. We have analysed two members of
this protein family, PfRh2a and PfRh2b, and show they undergo a complex series of proteolytic cleavage events before and
during merozoite invasion. We show that PfRh2a undergoes a cleavage event in the transmembrane region during invasion
consistent with activity of the membrane associated PfROM4 protease that would result in release of the ectodomain into
the supernatant. We also show that PfRh2a and PfRh2b bind to red blood cells and have defined the erythrocyte-binding
domain to a 15 kDa region at the N-terminus of each protein. Antibodies to this receptor-binding region block merozoite
invasion demonstrating the important function of this domain. This region of PfRh2a and PfRh2b has potential in a
combination vaccine with other erythrocyte binding ligands for induction of antibodies that would block a broad range of
invasion pathways for P. falciparum into human erythrocytes.
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Introduction
Invasion of apicomplexan parasites into host cells is a complex
process involving multiple ligands stored in apical organelles
known as micronemes and rhoptries (for review see [1]). The
ligands are released from these compartments onto the invasive
zoite form of the parasite during egress or invasion of the host cell
where they are able to bind receptors. After initial contact
involving low affinity interactions the parasite reorients so that the
apical end is abutting the host cell membrane and a tight junction
is formed with the invading parasite membrane. The tight junction
involves specific parasite ligands and this structure is ultimately
linked to the actomyosin motor that provides the force required for
invasion (see for review [2]). Entry into the host cell is mediated by
movement of the tight junction across the surface to the posterior,
where membrane fusion completes formation of a parasitophorous
vacuole surrounding the internalised parasite.
Whilst some apicomplexan parasites, such as Toxoplasma gondii,
are able to invade many different host cells Plasmodium spp.
merozoites have an exquisite preference for red blood cells and this
is mediated by specific parasite ligand-host receptor interactions.
In the case of P. falciparum, the causative agent of the most severe
form of malaria in humans, this involves at least two protein
families. Firstly, the erythrocyte binding-like (EBL) proteins have
been shown to be important in merozoite invasion by inhibition
with specific antibodies and also analysis of P. falciparum parasites
in which the gene encoding them have been disrupted [3,4,5,6,7].
This family consists of EBA-175 (MAL7P1.176), EBA-181
(JESEBL) (PFA0125c), EBL-1 (GenBank: AAD33018.1), EBA-
165 (PEBL) (PFD1155w) and EBA-140 (BAEBL) (MAL13P1.60)
[4,8,9]. These proteins belong to a larger family of proteins in
Plasmodium spp. that includes the Duffy binding proteins (DBP) in
P. vivax and P. knowlesi [9]. EBA-175 and EBA-140 bind to
glycophorin A and C respectively in a sialic acid-dependent man-
ner and are responsible for specific invasion pathways through
these receptors [9,10,11,12]. Two other ligand-receptor interac-
tions requiring sialic acid are EBA-181, which binds to an un-
known receptor [13] and EBL-1 to glycophorin B, an interaction
of lower significance since approximately 50% of P. falciparum
strains analysed expressed a truncated protein [14]. EBA-165
appears to be a transcribed pseudogene as the protein has not been
shown to be expressed in any P. falciparum parasites to date [15].
The second family of proteins important for invasion of mer-
ozoites is the reticulocyte binding-like (RBP) proteins of Plasmodium
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1 and 2 proteins [16,17]. These proteins have been implicated in
mediating reticulocyte preference for P. yoelii and P. vivax.I nP.
falciparum, this family includes PfRh1 (PFD0110w), PfRh2a
(PF13_0198), PfRh2b (MAL13P1.176), PfRh3 (PFL2520w),
PfRh4 (PFD1150c) and PfRh5 (PFD1145c) [6,7,18,19,20,21,
22,23]. The PfRh3 gene is a transcribed pseudogene in P. falciparum
parasites whilst the other genes are differentially expressed and are
localised to the neck of the rhoptries before merozoite invasion
[6,24]. The PfRh1, PfRh4 and PfRh5 proteins bind to specific
receptors on the erythrocyte and the physical properties of these
have been defined by analysis of binding and invasion into
neuraminidase-, trypsin- and chymotrypsin-treated erythrocytes
[7,18,19,20,22,25,26,27,28,29]. PfRh1 binds to a neuraminidase-
sensitive receptor [18,19] whilst PfRh4 and PfRh5 bind different
receptors in a sialic acid-independent manner ie. neuraminidase-
resistant [25,26,28]. PfRh2a and PfRh2b have not been directly
demonstrated to bind erythrocytes but analyses of P. falciparum
gene knockout strains have shown that the latter protein functions
in merozoite invasion [6]. In contrast, PfRh2a appears to be
inactive in some strains of P. falciparum despite expression of the
protein [6,30]. Recently, Complement receptor 1 (CR1) has been
identified as a receptor for P. falciparum invasion of erythrocytes
[31,32] and PfRh4 binds directly to this receptor to mediate mer-
ozoite invasion [28].
P. falciparum strains are able to utilise variable patterns of alter-
nate host receptors and this provides a mechanism of phenotypic
variation to evade host immune responses and circumvent the
polymorphic nature of receptors on the erythrocyte surface within
the human population [6]. This is mediated by differential
expression and function of both the EBL and PfRh proteins
[6,25,33,34]. P. falciparum strains show a wide range of PfRh1 ex-
pression as a result of amplification of the gene and disruption of
ligand expression by gene knockout results in increased function of
other ligands from these families [7]. Both PfRh2a and PfRh2b are
highly expressed in some P. falciparum lines; however, cannot be
detected in others despite the presence of intact genes suggesting
that they are differentially silenced [6,35]. It has not yet been
demonstrated that these ‘silenced’ genes can be activated. In con-
trast, PfRh4 is also silenced in some lines and activated in a small
proportion of the population and these can be selected either by
disruption of the EBA-175 gene or alternatively growth of the
parasites in neuraminidase-treated erythrocytes [25,36]. These
selected parasites are more dependent on the PfRh4 ligand and
CR1 receptor for merozoite invasion and this ability to switch
‘invasion pathways’ provides an additional mechanism of phe-
notypic variation for entry into the host cell [25,32].
Proteolytic cleavage of P. falciparum ligands plays an essential
role in their function and fragments of the EBL and PfRh proteins
are released into the supernatant during the invasion process
[7,37]. It has been demonstrated that members of the EBL and
PfRh family of proteins can be cleaved in the transmembrane
region by the membrane associated protease rhomboid 4
(PfROM4) (PFE0340c) which has implicated this protease in
release of these proteins during invasion [29,37,38]. EBA-175,
PfRh1 and PfRh4 appear to be cleaved by PfROM4 as the
expected products are produced during invasion [29,37]. PfRh1
and PfRh4 undergo a series of processing events during merozoite
development resulting in a number of fragments and this appears
to be critical for their function [29].
In this work, we show that PfRh2a and PfRh2b undergo a
complex series of proteolytic cleavage events and that a defined
region of the N-terminus directly binds erythrocytes. We show this
region is critical to the function of these ligands as antibodies
inhibit receptor binding and merozoite invasion.
Results
PfRh2a and PfRh2b undergo processing in the schizont
stage of P. falciparum
PfRh2a and PfRh2b proteins are identical for most of the N-
terminus and completely diverge in sequence 42 and 54 kDa
respectively from the C-terminus (Figure 1A) [19,20]. To deter-
mine the role of proteolytic cleavage in these proteins a panel of six
recombinant proteins were produced that spanned PfRh2a and
PfRh2b and polyclonal and monoclonal antibodies raised (Figure
1A). The six recombinant proteins were in addition to two other
fusion proteins that had previously been used to generate the rabbit
antibodies, R2A9 and R2A11 (Figure 1A) [20]. Polyclonal (R1090,
PfRh2b-specific and R1088, PfRh2a-specific) and monoclonal
antibodies (4B7, PfRh2b specific and 8F9, PfRh2a specific) were
made to the unique regions of PfRh2a and PfRh2b. Additionally,
polyclonal (R1070, R1170 and R1171) and monoclonal antibodies
(6F12, 1F10, 3A2) were derived to the common N-terminus of both
proteins (Figure 1A). The specificity of these antibodies was con-
firmed by immunoblot using parasite lines 3D7 and FCR3, in which
the former expresses PfRh2a and PfRh2b whilst the latter does not
(Figure 1B) [7]. The monoclonal antibody 3A2 bound to protein
bands corresponding to that expected for both PfRh2a and PfRh2b
which were absent in FCR3 parasites. In contrast, the 4B7 mono-
clonal antibody bound to the protein bands corresponding to
PfRh2b, which were absent in FCR3. The 8F9 monoclonal
antibody bound specifically to bands expected for PfRh2a expressed
in 3D7. The R1171 rabbit polyclonal bound to both major PfRh2a
and b protein bands. The R1090 and R1088 antibodies were
specific to PfRh2b and PfR2a respectively. Therefore the monoclo-
nal antibody 4B7 and the polyclonal antibody R1090 are specific for
PfRh2b whilst the monoclonal antibody 8F9 and polyclonal
antibody R1088 reacts specifically with PfRh2a. In contrast, the
monoclonal antibody 3A2 and polyclonal rabbit antibodies R1171
react with both PfRh2a and PfRh2b.
Whilst the large PfRh2a and PfRh2b proteins were detected
previously [6,7,18,19,20,21,22,23], antibodies to the N-terminus
have not been available (Figure 1C). Immunoblots of 3D7 culture
supernatants unexpectedly identified an 85 kDa protein using the
Author Summary
The causative agent of the most severe form of malaria in
humans is the protozoan parasite Plasmodium falciparum.
These parasites are carried by a mosquito that infects
humans during feeding resulting in injection of sporozoite
forms that infect and develop in the liver into the
merozoite stage. The merozoites are released into the
blood stream where they invade erythrocytes in which
they can grow and divide. Invasion of the red blood cell by
P. falciparum merozoites involves a cascade of protein-
protein interactions. The P. falciparum reticulocyte bind-
ing-like homologue proteins (PfRh or PfRBL) are an
important protein family involved in binding to specific
receptors on the red blood cell. We have analysed two
members of this protein family, PfRh2a and PfRh2b, and
show that they undergo a complex series of cleavage
events before and during merozoite invasion. We have
defined the region of these ligands that bind red blood
cells and show that antibodies to this receptor-binding
region block merozoite invasion demonstrating the
important function of this domain.
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PLoS Pathogens | www.plospathogens.org 2 June 2011 | Volume 7 | Issue 6 | e1002075Figure 1. Both the PfRh2a and PfRh2b proteins are processed to release an 85 kDa product into culture supernatants. (A) Schematic
representation of the antibodies used in this study and the approximate location of the processing event leading to a common 85 kDa fragment and
unique 285 kDa PfRh2a and 297 kDa PfRh2b products. The C-terminal transmembrane domains of both the PfRh2a and PfRh2b proteins are shown.
Antibodies prefaced with the letter ‘R’ are Rabbit antibodies while the other antibodies are Mouse monoclonals. (B) Culture supernatants contain
unprocessed and large processed fragments for both PfRh2a and 2b proteins. Western blots probed with six antibodies recognising a PfRh2 common
region (3A2, R1171), Rh2a-specific (8F9, R1088) and PfRh2b-specific (4B7, R1090) regions are shown. The 3A2 and R1171 antibodies detect all four
PfRh2a and PfRh2b processed and unprocessed proteins in 3D7 supernatants. The 4B7 and R1090 antibodies detect the processed 297 and
unprocessed 382 kDa PfRh2b proteins. The 8F9 and R1088 antibodies detect the processed 285 and unprocessed 370 kDa PfRh2a proteins. Apart
from weak reactivity with both unprocessed and processed PfRh2b proteins with the 4B7 and R1090 antibodies, no proteins from FCR3 supernatants
were detected. As a loading control, EBA-175 antibodies were used to probe the same blots. (C) Only N-terminal antibodies detect the 85 kDa
processed product both in culture supernatants and schizonts. Four different N-terminal antibodies detect the 85 kDa processed product in 3D7-
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and monoclonals 6F12 and 1F10) (Figure 1A and 1C). The same
sized 85 kDa protein was also detected in purified 3D7 schizonts,
suggesting that this processing event occurred before rupture and
release of merozoites for invasion. To confirm that R1070, R1170,
1F10 and 6F12 antibodies were detecting the same 85 kDa
polypeptide from the PfRh2a and PfRh2b proteins we immuno-
precipitated with each and probed immunoblots with the other
antibodies (Figure 1D). The results show that the four antibodies
can specifically immunoprecipitate the 85 kDa processed PfRh2a/
2b fragment and that this can be detected by immunoblot using
the other antibodies. Therefore the full length PfRh2a (370 kDa)
and PfRh2b (382 kDa) proteins are processed into two major
peptides, during late schizont development, of approximately 85/
285 kDa for PfRh2a and 85/297 kDa for PfRh2b.
PfRh2a and PfRh2b processing occurs in a post-Golgi
compartment
Previously, it has been shown that processing of PfRh2a and
PfRh2b was brefeldin A (BFA) sensitive implying that a protease
cleavage event occurred post-Golgi in the schizont [24]. To show
that cleavage and release of the 85 kDa polypeptide derived from
the full-length PfRh2a and PfRh2b proteins occurred after
trafficking through the Golgi, we radiolabelled 3D7 schizonts in
the presence or absence of BFA and immunoprecipitated with an
antibody (R1170) to the 85 kDa fragment (Figure 2 A). BFA
blocked appearance of the N-terminal 85 kDa polypeptide
showing that this fragment was derived by processing from the
full-length proteins, and also suggests this occurs at the schizont
stage before merozoite egress (Figure 2A). To confirm that pro-
cessing occurs prior to merozoite egress, 3D7 parasites were
radiolabelled in the presence or absence of the cysteine protease
inhibitor E64, an inhibitor of schizont rupture [39,40]. These ex-
periments showed that E64 had no effect on cleavage of the
PfRh2a/b proteins to the 85 kDa polypeptide consistent with this
processing event occurring in schizonts prior to merozoite egress
(Figure 2A).
To further confirm that the 85 kDa fragment was produced by
processing of the full-length PfRh2a and PfRh2b proteins we used
pulse chase experiments followed by immunoprecipitation with an
N-terminal antibody (Figure 2B). Synchronized 3D7 schizonts
were radiolabelled with [
35S]methionine/cysteine and chased with
the same nonradioactive amino acids. Samples were taken
following the commencement of cold chase and immunoprecip-
itated with R1170, an antibody to the 85 kDa fragment. At the
beginning of the chase there was little of the 85 kDa fragment, but
this accumulated over the time points peaking at 15 minutes
(Figure 2B). A protein band of approximately 380 kDa, that co-
migrated with the large unprocessed PfRh2a/b proteins (Figure
2B), was very faintly visible that decreased in its accumulation
concomitant with the increase in the 85 kDa band suggesting it is
the precursor protein. However, this large molecular weight band
was not heavily labelled consistent with the very low levels of
the full-length PfRh2a/b proteins observed in immunoblots
(Figure 1B). The identity of the radiolabelled chased 85 kDa
fragment was confirmed by Western blot with the 6F12 antibody
(Figure 2B). Taken together these data show that the full-length
derived supernatants and schizonts but not in FCR3 supernatants. The same blots were reprobed with EBA-175 antibodies as a loading control. (D)
Four different N-terminal antibodies immunoprecipitate the 85 kDa product. 3D7 culture supernatants were immunoprecipitated with all four N-
terminal antibodies. Immunoprecipitates derived from rabbit antibodies were probed with mouse antibody 6F12 and immunoprecipitates derived
from mouse antibodies were probed with both rabbit antibodies.
doi:10.1371/journal.ppat.1002075.g001
Figure 2. Processing of the 85 kDa fragment is brefeldin A-
sensitive. (A) Sensitivity of the production of the 85 kDa fragment to
BFA and E64. Synchronised 3D7 schizont cultures were treated with BFA
at 5 ug/ml (methanol as control) or E64 at 10 mM (water as control) for
1 h before resuspending in methionine/cysteine-free medium and
[
35S]methionine/cysteine for a further 1 h with inhibitors as before.
Labelled parasites were then lysed and normal rabbit serum [(2)
control] or R1170 anti-85 kDa fragment antibody used for immunopre-
cipitations. The 85 kDa band is arrowed while two cross-reacting bands
at ,140 and ,220 kDa are asterisked. (B) The level of the 85 kDa
fragment peaks at a 15 min chase time. 3D7 schizonts were labelled
with [
35S]methionine/cysteine for 10 min, then chased for 0, 5, 15, 30
and 60 min. Samples were immunoprecipitated with normal rabbit
serum or R1170. The right panel shows 0 min samples probed with an
antibody to the 85 kDa fragment (6F12).
doi:10.1371/journal.ppat.1002075.g002
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schizont stage to produce an N-terminal 85 kDa fragment.
The 85 kDa processed form of PfRh2a and PfRh2b
co-localises and forms a complex with the corresponding
C-terminal regions
To determine if the 85 kDa polypeptide cleaved from the
PfRh2a and PfRh2b proteins in schizont stages co-localised with
the C-terminal fragments of each protein we used synchronised
parasites for immunofluorescence experiments. The PfRh2a spe-
cific monoclonal antibody 8F9 (detects the C-terminal polypep-
tide) and the R1170 rabbit antibody (detects the N-terminal
85 kDa domain) both showed an apical pattern with strong co-
localisation (Figure 3A). To determine if the 85 kDa fragment also
co-localised with the 297 kDa C-terminal PfRh2b polypeptide
parasites were dual stained with the monoclonal antibody 4B7
(detects the C-terminal PfRh2b protein) and R1170 (detects the N-
terminal 85 kDa of PfRh2a and PfRh2b) rabbit antibody. Both
antibodies showed a staining pattern of the apical end in
Figure 3. The 85 kDa processed form of PfRh2a and PfRh2b colocalises with the corresponding C-terminal regions in both
merozoite and schizont stages. (A) The 85 kDa product co-localises with the C-terminal PfRh2a product. Free merozoites or schizonts of the 3D7
parasite were dual stained with 8F9 anti-PfRh2a and R1170 anti-85 kDa antibodies. Both merozoites and schizonts give an apical staining pattern with
both antibodies, indicating co-localisation. Nuclei were stained with DAPI. (B) The 85 kDa product co-localises with the C-terminal PfRh2b product.
Parasites were dual stained with 4B7 anti-PfRh2b and R1170 anti-85 kDa antibodies. As for (A), both antibodies give a co-localised apical staining
pattern. (C) The 85 kDa product co-localises with both the PfRh2a and PfRh2b C-terminal products. Parasites were dual stained with 3A2 anti-PfRh2a/
2b and R1170 anti-85 kDa antibodies. As for (A), both antibodies give a co-localised apical staining pattern.
doi:10.1371/journal.ppat.1002075.g003
Function of PfRh2b in Invasion of P. falciparum
PLoS Pathogens | www.plospathogens.org 5 June 2011 | Volume 7 | Issue 6 | e1002075merozoites with clear co-localisation (Figure 3B). This suggested
that the PfRh2a and PfRh2b cleaved polypeptides had the same
subcellular co-localisation in schizont and merozoite stages. To
confirm this parasites were dual stained with an antibody rec-
ognising the PfRh2a and PfRh2b C-terminal polypeptides and the
85 kDa N-terminal domain using R1170 rabbit antibodies. Both
antibodies showed co-localisation in schizont and merozoite stages.
(Figure 3C). These results have confirmed that following cleavage
of PfRh2a and PfRh2b the 85 kDa N-terminal fragment and the
large C-terminal processed polypeptides co-localise in schizont and
merozoite stages of P. falciparum consistent with them existing as a
complex (Figure 3C).
To determine if the 85 kDa N-terminal region of PfRh2a and
PfRh2b formed a complex with the corresponding C-terminal
regions of each protein we used 3D7 schizont stage parasites in
immunoprecipitation experiments with the R2A9 polyclonal
antibodies (recognises C-terminal PfRh2a and PfRh2b domain)
(Figure 4). The precipitated proteins were detected in immuno-
blots using the monoclonal 6F12 that recognised the N-terminal
85 kDa domain as well as the full-length PfRh2a and PfRh2b
proteins (Figure 4A). The same immunoprecipitate probed with
the monoclonal 3A2 recognised the unprocessed and C-terminal
processed forms of PfRh2a and PfRh2b. Similar results were ob-
tained in immunoprecipitation experiments with culture superna-
tants (Figure 4B). We did similar experiments with 3D7D2a and
3D7D2b, parasites that lack expression of PfRh2a or PfRh2b
respectively, to determine if both proteins could form a complex
after N-terminal processing [6]. This confirmed that PfRh2a and
PfRh2b are both processed to yield the 85 kDa N-terminal
fragment and that this can form a complex with either the PfRh2a
or PfRh2b C-terminal domain and that these complexes are shed
into the culture supernatant during merozoite invasion of red
blood cells (Figure 4C and D).
Both the 85 kDa and 285/297 kDa C-terminal products of
Rh2a/Rh2b have multiple cysteine residues and to determine if
the complex formed between the N-terminal and C-terminal
polypeptides are held together through disulphide bonds we used
SDS-PAGE under non-reducing conditions and as a comparison
also under reduced conditions (Figure S1). Proteins from culture
supernatants were probed with antibodies that would detect the
PfRh2a and PfRh2b 85, 285 and 297 kDa polypeptides. These
proteins migrated at an identical size compared to that observed
under reducing conditions indicating the complex did not involve
disulphide bonds (Figure S1).
PfRh2a is C-terminally processed during merozoite
invasion
In order to follow the processing events before and after
merozoite invasion we attempted to tag the 39 end of the Pfrh2a
and Pfrh2b genes with haemagglutinin (HA) epitopes by single
crossover homologous recombination (Figure 5A) [41]. Unfortu-
nately, we were unable to select parasites in which the plasmid had
inserted into the Pfrh2b gene; however, this was successful for
Pfrh2a by transfection of W2mef parasites to derive the parasite
line W2mefRh2a-HA. Successful tagging was shown by immuno-
blots using anti-HA antibodies that detected two bands corre-
sponding to PfRh2a in the transfected line but not the parental
parasite (Figure 5B, left panel). This was confirmed using the
PfRh2a specific 8F9 monoclonal antibody that identified the
protein in W2mef, and an approximately 5 kDa larger protein,
corresponding to the epitope tag, in the W2mefRh2a-HA trans-
fected line (Figure 5B, right panel). Despite the small size of the
tag, its very acidic characteristics (pKi=3.80), may contribute to it
causing a significant mobility difference on SDS-PAGE between
the untagged and tagged versions of PfRh2a.
The ligand EBA-175 is cleaved by the protease PfROM4 at the
C-terminus in the transmembrane domain and we have dem-
onstrated that PfRh1 and PfRh4 are similarly cleaved during
merozoite invasion resulting in release of these processed proteins
into the supernatant [29,37]. To test if PfRh2a was cleaved we
purified ring stages less than 4 h post invasion to determine if the
transmembrane and cytoplasmic tail of PfRh2a, potentially re-
leased by PfROM4, could be detected using anti-HA antibodies
(Figure 5C). Immunoprecipitation of saponin or TNET solubilised
proteins using mouse anti-HA antibodies followed by detection
with rat anti-HA antibodies recognised a band of ,17 kDa
(Figure 5C). While the calculated size of the protein stub following
rhomboid cleavage within the transmembrane domain is 11 kDa,
the highly acidic nature of this stub (pKi=3.77) may cause it to
migrate aberrantly on SDS-PAGE. Hence this indicated that the
tagged PfRh2a protein was C-terminally cleaved during merozoite
invasion removing a stub migrating at ,17 kDa, corresponding in
size to the transmembrane, cytoplasmic tail and HA3 epitope tag,
consistent with the function of a PfROM protease to release the
ectodomain into the supernatant. In addition, a small proportion
(,5%) of unprocessed PfRh2a, migrating at over 250 kDa, was
observed indicating that proteolytic cleavage of the cytoplasmic
tail was highly efficient during merozoite invasion (Figure 5C). To
confirm that the HA-tagged PfRh2a C-terminal stub was carried
into the ring stage of the parasite, synchronous PfRh2aHA
parasites containing late schizont and early ring forms were dual
stained with anti-HA and PfRh2a/b common region antibodies
(Figure 5D). As expected the developing merozoites in schizont
stages showed apical staining with both anti-HA and anti-PfRh2a/
b ectodomain antibodies. Following invasion the ring stage
parasites reacted with anti-HA antibodies indicating that the
HA-tagged stub was carried into ring stages, while the PfRh2a/b
ectodomain was not, but instead was presumably released into the
culture supernatant. This was consistent with PfROM4 cleavage of
PfRh2a, and by inference PfRh2b, during merozoite invasion that
would result in shedding of the 285 kDa PfRh2a and 297 kDa
PfRh2b ectodomains and the 85 kDa N-terminal region into the
culture supernatant with the remaining cleaved stub carried into
the ring stage after invasion of the red blood cell (Figure 1B). This
result is consistent with previous data showing that the PfRh2a and
b putative recognition sequences for PfROM4 can be cleaved by
this protease when expressed in mammalian cells [29,37,38].
The PfRh2a/b C-terminal fragment localises to the
rhoptry neck and moving junction of merozoites
We have previously localised PfRh2a and PfRh2b to the neck of
the rhoptries in merozoites by immunoelectron microscopy [6].
However, it has not been technically possible to purify viable P.
falciparum merozoites in sufficient quantities to allow the localisa-
tion of proteins during invasion of erythrocytes by immunoelec-
tron microscopy. Recently, a new method has been developed for
purification of invasive merozoites and we used this to superinfect
erythrocytes to trap P. falciparum parasites during invasion for the
localisation of PfRh2a and PfRh2b by immuno-electron micros-
copy with antibodies to the conserved common domain of both
proteins. As we have described previously, PfRh2a/b was
predominantly retained within the rhoptry neck before active
invasion (Figure 6C, inset) [6]. After attachment, the results
suggested movement of PfRh2a/b from within the rhoptry neck to
the merozoite surface in some parasites, predominantly anterior
to the tight junction within the invasion pit. In other instances,
evidence for immunogold labelling at the tight junction was
Function of PfRh2b in Invasion of P. falciparum
PLoS Pathogens | www.plospathogens.org 6 June 2011 | Volume 7 | Issue 6 | e1002075Figure 4. Both PfRh2a and PfRh2b proteins form a complex with the 85 kDa processed product. (A) Proteins from synchronised 3D7
schizont stage parasites were immunoprecipitated with either R2A9 Abs or normal rabbit serum [(2) control]. Immunoprecipitated proteins were
separated by SDS-PAGE and probed with either 6F12 or 3A2 antibodies. The left panel shows that the R2A9 immunoprecipitate also brings down the
85 kDa processed product as detected with the 6F12 antibody, indicating that in 3D7 schizonts, the 85 kDa product is complexed with both the
285 kDa PfRh2a protein and the 297 kDa PfRh2b protein, as shown in the Right panel. (B) Proteins from 3D7 culture supernatants were
immunoprecipitated, separated by SDS-PAGE and probed as in (A) above. The result shows that the 285/85 kDa PfRh2a and the 297/85 kDa PfRh2b
complexes still remain in supernatant following invasion. (C–D) In order to confirm that both PfRh2a and PfRh2b were capable of complex formation,
proteins from culture supernatants of both 3D7D2a and 3D7D2b parasites were immunoprecipitated as before. The results show that both PfRh2b (C)
and PfRh2a (D) can form a complex with the 85 kDa processed product.
doi:10.1371/journal.ppat.1002075.g004
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36HA epitopes by 39 crossover recombination is shown. The human dihydrofolate reductase-thymidylate synthase (hdhfr) gene encodes resistance
to WR99210. The whole cassette that includes a promoter and terminator is labelled as hdhfr. The P.berghei dhfr 39 terminator region (PbDT 39) served
as the terminator for the gene being tagged. (B) Pfrh2a is tagged with 3HA. Proteins from schizont stages of the W2mef parasite or the line
expressing tagged PfRh2a (Rh2aHA) were separated by SDS-PAGE then probed with either anti-HA Abs (Left panel) or the 8F9 antibody to the PfRh2a
protein (Right panel). The anti-HA antibody detect two high molecular weight proteins specifically in the tagged line, a processed protein at
,295 kDa and the unprocessed protein at ,380 kDa. The protein detected at ,150 kDa is a cross-reacting protein found also in the untagged wild-
type parasite. (C) PfRh2a is C-terminally cleaved at invasion and the resulting stub carried into the Ring. The schematic diagram shows the C-terminal
cleavage, most likely due to a rhomboid protease, occurring within the transmembrane (TM) region of Rh2aHA parasites. The HA-tagged cytoplasmic
tail (CT) is also shown. A synchronised mixed schizont/Ring-stage culture, containing Rings ,4 h old, was sorbitol-synchronised to remove schizonts.
The young Rings were then lysed either with saponin or TNET, spun down, and both supernatant and pellet fractions collected. HA-containing
proteins from both supernatant fractions were immunoprecipitated with anti-HA Abs. Immunoprecipitated proteins together with proteins from the
saponin and TNET pellets were separated by SDS-PAGE, blotted, then probed with anti-HA antibodies. The C-terminally processed tail of ,18 kDa
was detected in both the saponin and TNET extracted ring fraction but not in the saponin-lysed pellet fraction. A cross-reacting protein at ,25 kDa
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for another PfRh family member, PfRh1 [6]. For a comparison we
also labelled free merozoites with EBA-175 antibodies as the PfRh
and EBL protein families appear to have overlapping functions in
erythrocyte invasion [[25,42]. The antibodies to EBA-175 dis-
played a micronemal localisation (Figure 6D) as has been shown
previously [43]. From attachment through to invasion localisation
was difficult to follow, but suggested that surface-released EBA-
175 capped the apical tip, with labelling seen in the invasion pit of
some parasites caught mid invasion (Figure 6D). A proportion of
EBA-175 labelling, however, remained within the apex of the
merozoite, even after initiation of invasion. The overlap in
function between EBL and PfRh proteins during invasion shown
previously, is consistent with the images shown here suggesting
that these proteins play an important role at or close to the tight
junction during merozoite invasion [25,42].
The 85 kDa cleaved PfRh2a and PfRh2b protein binds
erythrocytes
It has been suggested previously that the large PfRh2a and
PfRh2b proteins shed into culture supernatants did not bind red
blood cells and additional experiments using new antibody
reagents, generated in this study, was consistent with these results
(Figure S2) [6]. However, PfRh2b was functional in 3D7 parasites
as it was possible to inhibit invasion with antibodies to this protein
suggesting it interacted either directly or indirectly with a trypsin-
and neuraminidase-resistant erythrocyte receptor. Identification of
an 85 kDa fragment from both PfRh2a and PfRh2b raised the
possibility that this contained the erythrocyte binding domain. In
order to test this possibility we performed erythrocyte-binding
assays using culture supernatant from 3D7 and W2mef parasites
(Figure 7A). Using the anti-PfRh2a/b monoclonal 6F12 we
detected the 85 kDa protein from both 3D7 and W2mef after it
was eluted from red blood cells. This binding was trypsin-resistant
and partially chymotrypsin- and neuraminidase-sensitive which is
similar but not identical to the physical properties of the host
receptor determined previously by analysing PfRh2b parasites in
which the gene had been disrupted as well as inhibition of function
with specific antibodies for invasion into enzyme-treated erythro-
cytes [6]. Taken together these results show that the 85 kDa
PfRh2a and PfRh2b polypeptide contains the binding site for
human erythrocytes.
To confirm that the 85 kDa PfRh2a and 2b protein was able to
bind erythrocytes, we tested antibodies to this region (Figure 1) for
their ability to block binding of the 85 kDa protein to erythrocytes.
Rabbit antibodies (R1070 and R1170) and both the 6F12 and
1F10 monoclonals were used at concentrations from 0.1 to 1.0
ug/ul and only R1170 antibody efficiently blocked binding of
native PfRh2a/b to erythrocytes (Figure 7B). Normal rabbit
serum, polyclonal antibodies to other regions of the 85 kDa
domain (R1070, Figure 7B) and the monoclonal antibody 1F10
(Figure 7B) and 6F12 (data not shown) did not block binding. This
suggested that the binding region was located towards the C-
terminus of the 85 kDa polypeptide (Figure 1).
was seen only in the saponin fractions. (D) The HA-tagged stub is carried into ring stages. Young rings less than 4 h old and schizonts of the Rh2aHA
line were dual stained with 12CA5 anti-HA (Roche, Germany) and a common region antibody (R2A11, Figure 1). The PfRh2a/b ecto-domain is not
carried into rings, while the HA-tagged stub is carried into rings. Nuclei were stained with DAPI.
doi:10.1371/journal.ppat.1002075.g005
Figure 6. Immuno-electron microscopy localisation of PfRh2a and PfRh2b during merozoite invasion of human erythrocytes. (A) The
PfRh2a/2b proteins localise to the rhoptry neck and moving junction of merozoites. Transmission electron micrographs of pre- and mid-invasion
merozoites showing PfRh2a/b-specific immunogold labelling (white arrows). At the pre-invasion stage, PfRh2a/b localises to the rhoptry neck (inset),
while during mid-invasion, PfRh2a/b localises both to the moving junction and to the merozoite surface within the invasion pit. Scale bar=0.2 mm.
(B) The EBA-175 protein localises to the micronemes and apical tip of merozoites. At the pre-invasion stage, EBA-175 is located within micronemes
(inset), while during mid-invasion, EBA-175 can be located either at the apical tip or within the invasion pit. Scale bar=0.2 mm.
doi:10.1371/journal.ppat.1002075.g006
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In order to define the receptor binding region within the
85 kDa PfRh2a and b proteins we made a recombinant hexa-His
tagged protein of 15 kDa corresponding to amino acids 446 to 557
(rRh215). This protein fragment was located close to similar
regions of PfRh1 and PfRh4 that have been shown to bind
erythrocytes (Figure S3 and S4) [26,27,28,32]. Rabbit antibodies
(R1170) made to rRh215 that block binding of native PfRh2a and
b to erythrocytes have already been described above (Figure 7B).
The rRh215 fusion protein (Figure S5) bound to erythrocytes
whereas the 2b1 protein (Figure S5) from the C-terminal region of
PfRh2b showed no detectable binding (Figure 8A, 8B and 8C).
Additionally, we tested binding of a number of other recombinant
proteins corresponding to different regions of the PfRh2a, PfRh2b
and PfRh1 proteins and none of these regions showed binding to
red blood cells (Figure S6). The specificity of binding of the rRh215
fragment was shown by heat denaturing the fusion protein and
binding to erythrocytes (Figure 8B). Only the native fragment
bound erythrocytes. The rRh215 erythrocyte binding was resistant
to trypsin treatment but partially sensitive to chymotrypsin and
neuraminidase treatment, a pattern of binding we observed for the
P. falciparum expressed 85 kDa protein from culture supernatants.
The enzyme-treated erythrocytes were also used in binding assays
with parasite culture supernatants and the eluted proteins probed
with EBA-175 antibodies to ensure that the enzyme treatments
had been successful. To show that binding of rRh215 to eryth-
rocytes was specific we showed that Protein G-purified R1170
antibodies blocked binding (Figure 8D). The R1170 antibodies
Figure 7. The PfRh2a/b 85 kDa processed product binds erythrocytes and binding is inhibited by antibodies to the binding
domain. (A) Culture supernatant from both 3D7 and W2mef parasites was bound to untreated (Unt.), Low trypsin (0.067 mg/ml), High Trypsin
(1 mg/ml), neuraminidase (N) or chymotrypsin-treated (C) erythrocytes. Bound proteins were eluted with 1.5 M NaCl, separated on SDS-PAGE gels,
Western blotted and probed with an antibody to the 85 kDa product (6F12) and an antibody to EBA-175. PfRh2a/b binding to erythrocytes was
sensitive to neuraminidase and chymotrypsin, but resistant to both Low and High Trypsin concentrations. The input culture supernatant is labelled as
‘supn’. The lower panels probed with anti-EBA-175 Abs were included as a control for erythrocyte enzyme treatments as it is known that EBA-175
binding is neuraminidase sensitive, partially trypsin sensitive, but chymotrypsin resistant. (B) R1170 antibodies block native PfRh2a/b binding. Protein
G-purified R1070, R1170 or normal rabbit serum antibodies at final concentrations from 0.1 to 1.0 mg/ml or the 1F10 monoclonal antibody at final
concentrations from 0.1 to 0.5 mg/ml were preincubated with 3D7 culture supernatant before adding Untreated erythrocytes. Bound proteins were
eluted with 1.5 M NaCl, separated on SDS-PAGE gels, blotted and probed with an antibody (6F12) to the 85 kDa PfRh2a/b binding domain.
doi:10.1371/journal.ppat.1002075.g007
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fusion proteins. The rRh215 is located within the 85 kDa binding domain of PfRh2a/b. The processing event leading to the 85 kDa product is indicated
by the arrow. The 2b1 fusion protein is from a PfRh2b unique region at the C-terminus of the protein. The regions of the protein in black at the N and
C-termini represent the signal sequence and transmembrane domains respectively. (B)1mg rRh215 (native) or 1 mg denatured rRh215 (boiled) were
bound to untreated erythrocytes. Bound proteins were eluted with 1.5 M NaCl, separated on SDS-PAGE gels, blotted and probed with an antibody
(R1170) to the rRh215 fusion protein. Unbound proteins removed from the Untreated erythrocytes are also shown. (C)1mg rRh215 was bound to
untreated (Unt.), Low trypsin (0.067 mg/ml), High Trypsin (1 mg/ml), neuraminidase (N) or chymotrypsin-treated (C) erythrocytes. Bound proteins
were eluted, separated and probed as in B above. In the lower panel, both enzyme-treated and untreated erythrocytes were also probed with an
antibody to EBA-175 to ensure the enzyme treatments had been successful. Recombinant rRh215 binding to erythrocytes was partially sensitive to
neuraminidase and chymotrypsin, but resistant to both Low and High Trypsin concentrations. Unbound proteins removed from the Untreated
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almost full blocking at an antibody concentration of 0.26 mg/ml.
(Figure 8D). Therefore the erythrocyte-binding domain of PfRh2a
and b is located within the region defined by the 15 kDa rRh215
recombinant protein (Figure 8).
Antibodies to the PfRh2a/b binding site inhibit merozoite
invasion
Previously, it has been shown that antibodies to the C-terminus
of the PfRh2a and 2b common region inhibit merozoite invasion
and this confirmed that PfRh2b plays a direct role in this process
[6]. To determine if antibodies to rRh215 (R1170) inhibit invasion
we tested them in growth inhibition assays with normal and
trypsin-treated erythrocytes. The anti-rRh215 antibodies showed
approximately 18% inhibition of 3D7 invasion into normal eryth-
rocytes compared to no inhibition for antibodies (R1070) to a
second fusion protein away from the receptor binding site and
this inhibition was increased for trypsin-treated cells to 38%
(Figure 9A). The enhancement of inhibition occurred as a result of
removal of trypsin-sensitive receptors from erythrocytes thus
limiting those available. The PfRh2a/b erythrocyte receptor is
trypsin-resistant and removal of other receptors by this treatment
increased the potency of these inhibitory antibodies [6]. To show
that the inhibitory effect was specific and also to determine if it was
acting on the function of both PfRh2a and PfRh2b we used the P.
falciparum lines in which each gene had been specifically disrupted
(3D7D2a and 3D7D2b) or lacked expression of these proteins
(FCR3) [6] (Figure 9B). For untreated erythrocytes anti-rRh215
antibodies inhibited growth of 3D7D2a (which lacks expression of
PfRh2a) at about the same level as for, the 3D7 parent (Figure 9A
and B) and this was enhanced for both parasites when using
trypsin-treated erythrocytes. In contrast, the P. falciparum lines
3D7D2b (lacks expression of PfRh2b) and FCR3 (lacks expression
of PfRh2a and may express very low levels of PfRh2b) were not
inhibited (Figure 9B). Therefore the anti-rRh215 antibodies to the
receptor-binding site directly inhibit only PfRh2b function but not
PfRh2a function, confirming that PfRh2a was not functional in
3D7 [6,7,18,19,20,21,22,23].
Discussion
Invasion of host cells by Plasmodium spp. requires specific ligand-
receptor interactions to identify the appropriate target followed by
activation of the entry process (see for review [1]). Different P.
falciparum strains utilise alternative host receptors for invasion of
red blood cells by merozoites that provides a mechanism of
phenotypic variation for evasion of host immune responses and a
means to circumvent the polymorphic nature of the erythrocyte in
the human population [6]. The PfRh family of proteins are key
players in this process and some have been shown to bind to red
blood cells and function directly in merozoite invasion
[6,7,18,19,20,21,22,23]. PfRh2a and PfRh2b are important
members and they undergo a complex series of protease cleavage
events that is critical for their function in invasion. We have shown
that both proteins bind directly to erythrocytes and have defined
the region involved in receptor binding. Antibodies to the recep-
tor-binding region can directly inhibit merozoite invasion by
erythrocytes are also shown. The 2b1 fusion protein was bound to untreated erythrocytes. Bound proteins were eluted with 1.5 M NaCl, separated on
SDS-PAGE gels, Western blotted and probed with the 4B7 antibody raised to the 2b1 fusion protein. The 2b1 fusion protein showed no binding to
Untreated erythrocytes but was clearly present in the Unbound fraction. (D) R1170 antibodies block binding of rRh215 to erythrocytes. Protein G-
purified R1170 antibodies at final concentrations from 0.03 to 0.5 mg/ml were preincubated with 0.5 mg rRh215 fusion protein before adding Untreated
erythrocytes. Bound proteins were eluted with 1.5 M NaCl, separated on SDS-PAGE gels, Western blotted and probed with Protein G-purified R1170.
doi:10.1371/journal.ppat.1002075.g008
Figure 9. Antibodies to rRh215 block merozoite invasion. (A) R1170 antibodies to rRh215 block invasion of both untreated and Low trypsin-
treated erythrocytes. Protein G-purified IgG at 2 mg/ml final concentration from both R1070 and R1170 prebleeds and kill bleed sera were added to
3D7 parasites at the trophozoite stage together with target erythrocytes that were untreated or Low trypsin (0.067 mg/ml)-treated. Following
reinvasion in the presence of antibodies, cultures were continued to the trophozoite stage, when parasite numbers were determined in order to see
the effect of antibodies on invasion. Percent invasion in the absence of antibodies was adjusted to 100% invasion. Experiments were done at least
twice in triplicate. Error bars show the standard error of the mean. P-values were calculated using the Students t-test. (B) Antibodies to rRh215 block
invasion mediated by PfRh2b but not PfRh2a in 3D7 parasites. Protein G-purified IgG from R1170 serum at 2 mg/ml final concentration was added to
3D7D2a (express PfRh2b only), 3D7D2b (express PfRh2a only) and FCR3 (express neither PfRh2a nor PfRh2b) parasites at the trophozoite stage
together with target erythrocytes that were untreated or treated with 0.03 mg/ml Trypsin. Other details of the experiments were the same as in (A)
above.
doi:10.1371/journal.ppat.1002075.g009
Function of PfRh2b in Invasion of P. falciparum
PLoS Pathogens | www.plospathogens.org 12 June 2011 | Volume 7 | Issue 6 | e1002075blocking interaction with the host receptor demonstrating the im-
portant function of this domain.
The PfRh protein family plays an important role in merozoite
invasion and proteolytic processing appears to be critical to their
function [29]. In mature schizonts both PfRh2a and PfRh2b are
processed into an 85 kDa fragment that exists as a complex with the
C-terminal region of the corresponding protein. This processing
event occurs post-Golgi as it issensitiveto BFA, an inhibitor of SEC7,
resulting in retrograde protein transport and accumulation in the
endoplasmic reticulum [24]. However, the protease cleavage of
PfRh2a and b must occur before release of the merozoites from the
hostred bloodcellasitwasobservedinthe presenceofaninhibitorof
parasite egress (Figure 10). PfRh1 undergoes a similar processing
event in schizonts in which the 360 kDa protein is processed to
120 kDa and 240 kDa with the larger fragment containing the
erythrocyte binding region. Previously, it was not possible to show
that the 120 and 240 kDa PfRh1 fragments formed a complex in
schizonts, in contrast to PfRh2a and PfRh2b, and it was hypoth-
esised that the soluble 240 kDa fragment may complex with
another protein [29]. Whilst PfRh2a and PfRh2b processed com-
Figure 10. Schematic diagram illustrating post-Golgi and rhomboid processing of PfRh2a/2b proteins. (A) Full-length PfRh2a/2b
proteins are initially processed in a BFA-sensitive post-Golgi compartment to produce the 85 kDa fragment. The proteins are then transported to the
apical tip, where following invasion, processing within the transmembrane domain, most likely by PfROM4, occurs. (B) Schematic diagram illustrating
complex formation and the fate of various PfRh2a/2b processed products. Full-length PfRh2a and PfRh2b proteins are predicted to be 370 and
382 kDa respectively. Cleavage to produce the 85 kDa product and its subsequent complexing with the transmembrane-containing PfRh2a and
PfRh2b products, which occurs at the schizont stage, is shown. Following invasion, C-terminal rhomboid processing results in both complexed and
uncomplexed forms being shed into culture supernatant while the small processed stub of ,7 kDa in wild-type untagged parasites is carried into the
ring stage. A small amount of full-length unprocessed proteins (370/382 kDa) found both in schizonts and in supernatants following invasion, is
shown in faint outline.
doi:10.1371/journal.ppat.1002075.g010
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there appears to be a pool of free proteins similar to the situation
with PfRh1. In red cell binding experiments the 85 kDa region of
PfRh2a and PfRh2b binds but there was no detectable C-terminal
region suggesting either that the complex in culture supernatants
may be unstable and difficult to detect or that the 85 kDa region
undergoes conformational change that releases the associated C-
terminal region upon binding of the receptor on the red blood cell.
Our inability to detect these complexes with PfRh2a and PfRh2b
antibodies other than the R2A9 polyclonal would be consistent with
this possibility.
PfRh2a was processed during merozoite invasion at the
transmembrane region suggesting cleavage by PfROM4 protease
(Figure 10). PfROM4 has been shown to cleave the transmem-
brane of EBA-175, and PfRh1 and PfRh4 are also similarly
cleaved resulting in the ectodomains being released into the
supernatant during merozoite invasion [29,37]. These proteins are
substrates for PfROM4 when expressed in a heterologous system
suggesting they are all processed by this protease during invasion
[38]. It was not possible to show that PfRh2b was processed as we
were unable to tag the C-terminus; however, the evidence
supporting such an event for PfRh1, PfRh2a and PfRh4 suggests
that it was also cleaved by PfROM4 resulting in shedding of the
ectodomain from the merozoite surface [29] (Figure 10). This
processing event at the end of invasion would allow disengagement
of this protein family so that the merozoite can be completely
encased within the parasitophorous vacuolar membrane in the
early ring stage (Figure 10).
PfRh2b has been shown previously to mediate an invasion
pathway into erythrocytes using a chymotrypsin-sensitive and
trypsin/neuraminidase-resistant receptor Z [6]. This was defined
by invasion of P. falciparum into enzyme-treated erythrocytes and
inhibition with antibodies that specifically inhibit PfRh2b function.
We have not been able to demonstrate binding of either the
PfRh2a or PfRh2b C-terminal processed fragment suggesting that
it could function as a scaffold on which the 85 kDa N-terminus
complexes and this would allow potential signalling through the
transmembrane region as has been suggested by previous work
[6,16,44]. The 85 kDa domain of PfRh2a and b bound to eryth-
rocytes via a trypsin-resistant and chymotrypsin/neuraminidase-
sensitive receptor. The difference in neuraminidase sensitivity of
the putative receptor to that observed previously may be because
we are directly observing binding in comparison to previous in-
direct methods [6]. It is also possible that PfRh2b functions with a
co-receptor and as a result the physical properties of the receptor(s)
results in an average of the receptor and co-receptor attributes.
The use of co-receptors for entry of viruses into host cells is very
common and for example CCR5 and CXCR4 are utilised for
entry of HIV-1 with different isolates varying greatly in their
ability to use both [45]. It is possible that P. falciparum ligands are
also able to mediate invasion through co-receptors although none
have as yet been identified.
Previous data has shown that the PfRh2a ligand does not
function in the P. falciparum line 3D7 despite it being expressed and
capable of binding directly to erythrocytes [6]. This was shown by
disruption of PfRh2b (but not PfRh2a) expression in 3D7, that
resulted in abrogation of the inhibitory effect of anti-PfRh2a/b
antibodies demonstrating that only PfRh2b functioned in
merozoite invasion in these parasite lines. The only parasite line
in which PfRh2a has been shown to function is W2mef where it
appears to act to increase efficiency of invasion into neuramin-
idase-treated erythrocytes [30,46]. Antibodies to the PfRh2a and b
binding domains inhibit invasion of 3D7 only in the parental
parasites expressing both PfRh2a and PfRh2b and also 3D7D2a
that only expresses PfRh2b. This is in agreement with previous
results demonstrating that PfRh2a in 3D7 parasites was not
functional most likely due to the inactive cytoplasmic domain of
this protein [6]. Once the PfRh proteins bind to the erythrocyte it
has been hypothesised that they transmit a signal through the
cytoplasmic tail to activate subsequent events in merozoite inva-
sion and it is possible that this region of PfRh2a is incapable of
performing this function thus inactivating this specific invasion
pathway [6,16,44].
The receptor binding regions of PfRh1 and PfRh4 have been
localised to small regions at the N-terminus of each protein
[26,27,28]. Alignment of the binding-regions of PfRh1 and PfRh4
with other PfRh proteins has defined a semi-conserved domain
and this overlaps directly with the 15 kDa region of PfRh2a and b
that we have defined as the receptor binding domain [47]. This
suggests that the binding of each PfRh protein is contained within
the N-terminal semi-conserved region of each protein and that the
rest of these large proteins act as a scaffold for display and access to
this region. Previously a domain within the paralogous Py235
protein family has been identified as a ATP-binding domain
[48,49] and this plays a role in altering affinity of binding of these
proteins to the receptor. Whilst it has not been shown that ATP
binds to PfRh2a/b if it did in a similar way to the Py235 protein
the binding site would not be located in the 85 kDa receptor
binding region as it is within the C-terminal processed domain.
The PfRh proteins are located at the neck of the merozoite
rhoptry [6] and must move to the apical surface before invasion to
allow binding to their respective receptor on the surface of the
erythrocyte [29]. Currentevidence is consistent with an overlapping
and cooperative function for the EBL and PfRh family suggesting
they would be present insimilar locationsduringmerozoite invasion
[25,42]. Interestingly, the EBL family member EBA-175 is located
in micronemes [50] and presumably it and the PfRh proteins are
released at a similar timeonto the apicalend of the merozoite. Once
at the apical end of the merozoite these proteins would be free to
bind directly with specific receptors on the red blood cell and they
appear to play an important role not only in the apical interaction
of the merozoite but also commitment to irreversible attachment
that triggers downstream events of invasion [44,51]. Subcellular
localisation of PfRh2a/b and EBA-175 during merozoite invasion
of erythrocytes is consistent with an overlapping function and has
suggested these proteins are located at or near the tight junctionas it
movesover the surfaceofthe invadingparasite. This isinagreement
with previous results for the subcellular localisation of PfRh1 on
invading merozoites and suggests that once these proteins bind to
their receptors on the host cell they move with the tight junction
duringinvasionandtheectodomainwouldbe subsequently released
into the culture supernatant by ROM4 cleavage. This would infer
that the PfRh and EBL protein families could play an additional
role(s) after apical interaction during active invasion of the host cell.
Whilst this manuscript was under review a study was published
that also identified the 85 kDa processed N-terminus of PfRh2a
and PfRh2b and that this fragment bound to red blood cells in
agreement with our data [52]. They suggested that the C-terminal
region also showed some binding; however, we have not been able
to categorically show binding of this region to red blood cells in
this study and our previous work [6].
The PfRh family of proteins has been shown to be a target of
invasion inhibitory antibodies by the human immune system and
there is evidence that this is an important component of acquired
protective immunity that would act by blocking merozoite inva-
sion [53]. Previously, it has been shown that specific antibodies to
PfRh2a and b can inhibit merozoite invasion; however, these were
raised to a C-terminal region of PfRh2a and b [6]. Antibodies to the
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presumably by directly interfering with binding to the erythrocyte
surface. It has been shown that strains of P. falciparum can utilise
different combinations of PfRh proteins for merozoite invasion and
this mechanism of phenotypic variation is mediated by differential
expression and the ability of some parasites to activate specific PfRh
genes [6,25]. The ability of P. falciparum to use different invasion
pathways suggests that any PfRh protein by itself would not make an
effective vaccine and this is evident from the low level of growth
inhibition observed for antibodies to the receptor-binding region
[25,42]. Additionally, the proteins in the PfRh family are large
suggesting that specific functional regions need to be identified to
which antibodies can be raised that block merozoite invasion.
Indeed, recently it has been shown that immunisation of rabbits with
a combination of domains from EBA-175, PfRh2a/b and PfRh4
raised antibodies that were very potent inhibiting merozoite invasion
up to 90% [25,42]. Identification of the receptor-binding site of
PfRh2a and b that has been defined within a 15 kDa domain of
these large proteins suggests this region would be an excellent
candidate for inclusion in such a combination vaccine.
Materials and Methods
Ethics statement
Antibodies were raised in mice and rabbits under the guidelines
of the National Health and Medical Research Committee and the
PHS Policy on Humane Care and Use of Laboratory Animals.
The specific details of our protocol were approved by the Royal
Melbourne Hospital Animal Welfare Committee.
Parasite cultures
P. falciparum parasites were maintained in human O+ erythro-
cytes. 3D7 is a cloned line derived from NF54 obtained from
David Walliker at Edinburgh University. W2mef is a cloned line
derived from the Indochina III/CDC strain and FCR3 is a cloned
line. 3D7 parasites containing either a disrupted Pfrh2a gene
(3D7D2a) or a disrupted Pfrh2b gene (3D7D2b) have been des-
cribed previously [7]. Parasite cultures were synchronised with 5%
sorbitol [54].
Plasmids and transfection
The pHA3 plasmid enabled tagging of the PfRh2a gene with
three HA epitopes (pHA3) and has been described previously [29].
Genomic DNA from P. falciparum was used as template to amplify
a ,920 bp fragment from the C-terminal end of the PfRh2a or
PfRh2b genes by polymerase chain reaction (PCR) using the
oligonucleotide pairs [59AGCTagatctAAGACAAGAACAAGAA-
CGACT]/[59AGCTctgcagCAATTGTACTATCATTATCATT-
AAAAG] for Pfrh2a and [59AGCTagatctGTATGATCATGTT-
GTTTCAGA]/[59AGCTctgcagCAAAATATTTTTCTTCATT-
TTCATC] for PfRh2b [55] . The Bgl II and Pst I sites were used to
clone the PCR fragments into the pHA3 plasmid. P. falciparum was
transfected with 80 mg of purified plasmid DNA (Qiagen) and
selection for stable transfectants by single recombination crossover
was carried out as described [56].
Cloning, fusion proteins and antibodies
To generate recombinant proteins, DNA fragments were either
amplified from a codon-optimised (GeneArt, Germany) synthetic
gene for N-terminal proteins (Figure S7) or from 3D7 genomic
DNA by PCR and cloned into pET45. Bacterial cultures ex-
pressing the corresponding recombinant proteins were grown at
37uCt oA 600=0.5 then induced with IPTG at 30uC for 5 h. Cell
pellets were lysed in PBS/0.1% TX100/0.5 mg/ml lysozyme/
containing EDTA-free COMPLETE protease inhibitors (Roche).
DNAse I was added (10 mg/ml)beforesonication and centrifuged at
8000 g for 30 min at 4uC. For insoluble recombinant proteins the
inclusion bodies were resuspended in PBS/0.1% TX100/0.5 mg/
ml lysozyme, sonicated and washed with PBS/0.1% TX100 before
solubilisation and further purification as below. Recombinant
proteins that were soluble were further purified as outlined below.
The recombinant protein used to raise the antibody R1070, was
generated using oligonucleotide pairs [59AGCTggatccCAGCAA-
CAGCGTGCTGGAT]/[59AGCTctcgagTTAACGGTTCAGA-
TACAGATC] and amplified from a synthetic gene (Figure S7).
The insoluble recombinant protein as inclusion bodies was solu-
bilised in 6 M guanidine/100 mM phosphate pH 8/250 mM
NaCl, purified by Ni-NTA chromatography (Qiagen) and eluted
with 6 M guanidine/100 mM phosphate pH 4.5/250 mM NaCl.
The recombinant protein was refolded by diluting 100-fold in 2 M
urea/20 mM Tris pH 8/20 mM NaCl/1 mM reduced glutathi-
one/1 mM oxidised glutathione before further purification by ion-
exchange on a HiTRAP Q (GE Healthcare) column run in 2 M
urea/20 mM Tris pH 8. Elution was effected with a linear salt
gradient from 20 mM to 1 M NaCl. The purified protein was
dialysed against 0.5 M Urea/20 mM Tris pH 8/20 mM NaCl
before injection into animals.
The rRh215 recombinant protein (used to raise antibodies
R1170 and 1F10) was generated using oligonucleotide pairs [59A-
GCTggatccCAAAAAAAAATACGAAACCTATG]/[59AGCT-
ctcgagTTAATCGGTTTTTTCGATGTAGTTG] whilst the re-
combinant protein used to raise antibody R1088 and monoclonal
antibody 8F9 was derived using oligonucleotide pairs [59AGCTg-
gatccCCACATAAAAAGTAAACTAGAATC]/[59AGCTctcgag-
TTATGATCGAGAAAAATTTCTATC]. The soluble recombi-
nant proteins were purified over Ni-NTA resin by washing with a
buffer containing 50 mM phosphate pH 8/300 mM NaCl/10
mM imidazole and elution with 50 mM phosphate pH 8/300
mM NaCl/300 mM imidazole. Further purification was achieved
by size exclusion chromatography on a Superdex 75 column (GE
Healthcare).
The recombinant protein used to raise monoclonal antibody
6F12 was obtained by using the oligonucleotide pair [59AGCTg-
gatccCGAAAGCTATGTGATGAAC]/[59AGCTctcgagTTAG-
CTGGTGTTCAGAATGG] and amplified from a synthetic gene
(Figure S7). Washed inclusion bodies were solubilised in 6 M
guanidine/100 mM phosphate pH8/250 mM NaCl, purified over
Ni-NTA resin before elution of fusion protein with 6 M gua-
nidine/100 mM phosphate pH 4.5/250 mM NaCl. The fusion
protein was refolded by dilution 100-fold in 2 M urea/20 mM
Tris pH 8/20 mM NaCl. The partially purified protein was con-
centrated by TCA precipitation before running in a SDS-PAGE
gel and elution of the protein from the acrylamide for injection
into animals.
The recombinant protein used to raise antibody R1171 was
generated using the oligonucleotide pair [59AGCTggatccC-
TATGTAGATGTGGACGTTTCC]/[59AGCTctcgagTTAAA-
TGTCCTTATTTTTTTCATCC]. Washed inclusion bodies were
solubilised in 6 M guanidine/100 mM phosphate pH 8/250 mM
NaCl, purified over Ni-NTA resin before elution of fusion protein
with 6 M guanidine/100 mM phosphate pH 4.5/250 mM NaCl.
The fusion protein was refolded by dilution 100-fold in 25 mM
Tris pH7.4/20 mM NaCl, before further purification by ion-
exchange on a HiTRAP Q column run in 20 mM Tris pH 7.4/
20 mM NaCl. Elution was effected with a linear salt gradient from
20 mM to 1 M NaCl. The purified fusion protein was dialysed
against 20 mM Tris pH 7.4/20 mM NaCl before injection into
animals.
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and monoclonal 4B7) was generated using oligonucleotide pairs
[59AGCTggatccCAAGATAGATGAAAGTATAACTAC]/59AG-
CTctcgagTTAGTTTGAATACCTTTCATTATTG]. The solu-
blerecombinantproteinwaspurifiedoverNi-NTAresinbywashing
with a buffer containing 50 mM phosphate pH8/300 mM NaCl/
10 mM imidazole before elution with 50 mM phosphate pH
8/300 mM NaCl/300 mM imidazole. Further purification was
achieved by size exclusion chromatography on a Superdex 75
column (GE Healthcare). Final purification was achieved by ion-
exchange on a HiTRAP Q column run in 20 mM Tris pH 8.
Elution was effected with a linear salt gradient.
Purified fusion proteins were used to immunise rabbits and
mice. Rabbit immunoglobulins were purified on Protein G-
Sepharose and dialysed against PBS. Sera from mice immunised
with fusion proteins were screened by ELISA against the fusion
protein and by Western blot against late-stage parasite proteins.
Splenic fusions from positive mice resulted in monoclonal
antibodies (WEHI Monoclonal Antibody facility). The R2A9
and R2A11 antibodies have been described previously [20]. The
monoclonal antibody 3A2 was raised using the GST fusion protein
2A9 previously described and used to generate R2A9 antibodies.
The anti-His antibodies used were a pentaHis mouse monoclonal
(Qiagen) and the anti-HA antibodies used were either the mouse
monoclonal 12CA5 or the rat monoclonal 3F10 (Roche Applied
Science).
Parasite proteins, SDS-PAGE and immunoblot analysis
Culture supernatants enriched in proteins released during
merozoite invasion were obtained by synchronisation of parasite
cultures followed by treatment with trypsin and neuraminidase in
order to prevent reinvasion of erythrocytes following schizont
rupture, as described [7]. In some cases, culture supernatants were
made by allowing schizont rupture of synchronised late stage
cultures at high parasitaemia, without trypsin and neuraminidase
treatment. Total proteins from schizont stage parasites were
obtained by synchronisation and further cultured until mature
schizonts were present. Parasite proteins were then obtained by
saponin lysis of erythrocytes. All parasite preparations were made
in the presence of COMPLETE protease inhibitors (Roche).
Proteins were separated on either 3–8% Tris Acetate (for large
proteins) or 4–12% Bis Tris with MES buffer (for small proteins)
SDS-PAGE gels (Invitrogen). Western blotting onto nitrocellulose
(0.45 mm, Schleicher and Schuell) was performed according to
standard protocols and blots were processed with a chemilumi-
nescence system (ECL, Amersham).
P. falciparum radiolabelling
Mature 3D7 schizonts from highly synchronous cultures were
metabolically radiolabelled with 200 uCi/ml [
35S]methionine/
cysteine as described previously [57]. To analyse the effect of
brefeldin A (BFA, Sigma) on PfRh2a/b processing, BFA at 5 ug/
ml or an equal volume of methanol was added to cultures for 1 h.
Cultures were then spun down and resuspended in one fifth
volume of methionine/cysteine-free medium, containing methanol
or BFA as before and 200 mCi/ml [
35S]methionine/cysteine for
1 h at 37uC. Labelled parasites were washed twice with PBS,
uninfected erythrocytes lysed with 0.1% saponin and labelled
schizonts re-washed with PBS.
To analyse the effect of E64 (trans-epoxysuccinyl-L-leucyla-
mido-(4-guanidino)butane, Sigma) on PfRh2a/b processing, E64
at 10 mM or an equal volume of water was added to cultures under
identical conditions to those described for BFA treatment.
Pulse-chase experiments
Mature 3D7 schizonts from highly synchronous cultures were
labelled for 10 min then chased as previously described [57].
Chase samples were taken at t=0, 5, 15, 30 and 60 min and fro-
zen directly at 270uC.
Immunoprecipitation
Radiolabelled saponin-lysed parasites from both BFA and E64
experiments were lysed in 10 volumes TNET (1% TX100,
150 mM NaCl, 10 mM EDTA, 50 mM Tris pH7.4) containing
COMPLETE (Roche) protease inhibitors. Lysates were sonicated
and clarified by centrifugation. Radiolabelled pulse-chase samples
were instead solubilised in five volumes of Denaturing buffer (1%
SDS, 50 mM Tris pH8.0, 5 mM EDTA, COMPLETE protease
inhibitors). Samples were boiled, clarified by centrifugation, then
the clarified supernatants diluted 10-fold in TNET + COM-
PLETE inhibitors.
All immunoprecipitations of parasite proteins were carried out
in a 2-step procedure by first adding antibodies, then capturing
antigen:antibody complexes with ProteinG-Sepharose. Parasite
proteins from schizont stages were obtained by first saponin-lysing
synchronised cultures followed by schizont solubilisation with
TNET. Immunoprecipitations from culture supernatants directly
or from cold or radiolabelled TNET lysates were all carried out by
the same 2-step procedure. Washed immunoprecipitates were
separated by SDS-PAGE, blotted to nitrocellulose, then probed
with antibodies of a different species to the immunoprecipitating
antibodies, to avoid reactivity with immunoglobulin heavy and
light chains. For experiments in Figure 5C, young Rings less than
4 h old were obtained by sorbitol synchronising a late schizont/
Ring stage culture to remove schizonts. The Rings were then lysed
either with 0.1% saponin or TNET, spun down, and both
supernatant and pellet fractions collected. HA-containing proteins
from both supernatant fractions were immunoprecipitated with
anti-HA Abs. Immunoprecipitated proteins together with proteins
from the saponin and TNET pellets were separated by SDS-
PAGE, blotted, then probed with HRP-labelled anti-HA Abs.
Indirect immunofluorescence and immunoelectron
microscopy
Light microscopy was performed with synchronised parasites at
schizont, merozoite and ring stages. Ring stages were fixed in
solution with 4% paraformaldehyde and 0.0075% glutaraldehyde
(ProSciTech) as described [58]. Merozoites were obtained by air-
drying smears of late-stage parasites, then fixing either in 100%
methanol at 220uC. Schizonts were either fixed with paraformal-
dehyde/glutaraldehyde or in methanol. For dual-colour fluores-
cence, fixed parasites in solution or on slides were blocked in 3%
BSA in PBS, before both primary antibodies were added. Parasites
were washed, secondary Alexa Fluor 488/594 Abs added, then
mounted with VectaShield (Vector Laboratories) containing 1 mg/
ml DAPI. Images were captured with a Zeiss LSM5 Live micro-
scope with an AxioCam camera and Axiovision 4.7 software. For
paraformaldehyde/glutaraldehyde-fixed parasites, single z-stacks
shown were processed with AxioVision 4.7 deconvolution software.
Images from methanol-fixed parasites were not deconvolved.
For immunoelectron microscopy, free or invading merozoites
were fixed in 1% glutaraldehyde (ProSciTech, Australia) on ice for
30 min. Samples were pelleted in low-melt agarose before being
transferred into water, dehydrated in ethanol and embedded in
LR Gold Resin (ProSciTech, Australia). Following polymerization
by benzoyl peroxide (SPI-Chem, USA) samples were sectioned on
a Leica Ultracut R ultramicrotome (Wetzlar) and then prepared
Function of PfRh2b in Invasion of P. falciparum
PLoS Pathogens | www.plospathogens.org 16 June 2011 | Volume 7 | Issue 6 | e1002075for imaging with 2% aqueous uranyl-acetate followed by 5% triple
lead and observed at 120 kV on a Philips CM120 BioTWIN
Transmission Electron Microscope. PfRh2 proteins were stained
with the 2A9 antibody (Figure 1) while EBA-175 was stained with
an antibody to the C-terminal cysteine-rich region.
Erythrocyte binding assay
Erythrocyte binding assays using enriched culture supernatant
from parasites were performed as described previously [20]. For
binding assays to enzyme treated erythrocytes, erythrocytes were
incubated with neuraminidase (66.7 mU/ml), high trypsin (1.0
mg/ml), Low trypsin (0.067 mg/ml) and chymotrypsin (1.0 mg/
ml) for 1 hr at 37uC, then washed prior to the addition of soybean
trypsin inhibitor at 0.5 mg/ml for 10 min at 37uC. Treated eryth-
rocytes were subsequently washed three times and added to the
binding assay as described above. Bound proteins eluted with
1.5 M NaCl were separated on SDS-PAGE gels, Western blotted,
then probed with anti-PfRh2 or anti-EBA-175 antibodies.
Growth inhibition assay
Growth inhibition assays were performed with modifications of
a described method [59]. Briefly, twice-synchronised trophozoite
stage parasites were added to either untreated target erythrocytes
(at a final parasitemia of 0.5%) or to trypsin-treated erythrocytes
(at a parasitemia of 1%) and haematocrit of 2% in 45 ml of culture
medium in 96 well round bottom microtiter plates (Becton
Dickinson, U.S.A.). 5 ml of purified antibody was added to a final
concentration of 2 mg/ml. After incubation with antibodies for 1
cycle of parasite growth (,48 h), parasites were stained with
ethidium bromide (10 mg/ml final), and the parasitaemia of each
well determined by flow cytometry using a FACSCalibur with a
plate reader (Becton Dickinson, U.S.A.). At least two independent
assays in triplicate were performed. Data was analysed using
FlowJo software (Tree Star Inc). Growth was expressed as a per-
centage of the parasitaemia in the presence of the Protein-G
purified antibodies of the prebleed serum of the same rabbit also at
a final concentration of 2 mg/ml. Trypsin treatment of erythro-
cytes was carried out as described previously [7].
Accession numbers
eba-175 (MAL7P1.176); eba-181 (JESEBL) (PFA0125c); ebl-1
(GenBank: AAD33018.1); eba-165 (PEBL) (PFD1155w); eba-140
(BAEBL) (MAL13P1.60); Pfrh1 (PFD0110w); Pfrh2a (PF13_0198);
Pfrh2b (MAL13P1.176); Pfrh3 (PFL2520w); Pfrh4 (PFD1150c);
Pfrh5 (PFD1145c); Pfrom4 (PFE0340c).
Supporting Information
Figure S1 The PfRh2a and PfRh2b complexes are not held
together by disulphide bonds. Supernatant proteins from the 3D7
parasite were separated by SDS-PAGE under both reducing and
non-reducing conditions, then probed with antibodies to the
85 kDa fragment (R1070), a common C-terminal product (R2A9),
PfRh2a (R1088) and PfRh2b (R1090). Unprocessed PfRh2b and
PfRh2a are labelled as UP 2b and UP 2a respectively. The 297 kDa
PfRh2b and 285 kDa PfRh2a products are also labelled. The
85 kDa fragment appears to run as a doublet under non-reduced
conditions.
(EPS)
Figure S2 The 285 kDa PfRh2a and 297 kDa PfRh2b products
do not bind erythrocytes. (A) Location of antibodies used in Panel
B. (B) Western blots showing that the large C-terminal PfRh2a/b
products do not bind erythrocytes. Both 3D7 (express both
PfRh2a/b proteins) and FCR3 (do not express either PfRh2a or b)
supernatant proteins were separated by SDS-PAGE and probed
either with 3A2, 8F9 or 4B7 antibodies (right panels). The same
supernatant proteins were also used in erythrocyte binding assays.
Eluted proteins were separated by SDS-PAGE and probed with
the same antibodies as above (left panels).
(EPS)
Figure S3 The PfRh proteins fall into two groups based on the
alignment of conserved cysteine residues. An alignment of the first
400 amino acids of the PfRh proteins [6,7,18,19,20,21,22,23]
reveals a number of conserved Cys residues, shown as lines above
the genes, that split the proteins into 2 groups, the PfRh2/Rh3
and the PfRh1/Rh4 groups. The PfRh2/PfRh3 group has four
conserved cysteines, though the Pfrh3 gene also has a fifth cysteine
like the PfRh1/PfRh4 group. The Pfrh3 pseudogene with a
number of internal stop codons, is labelled with an asterisk since a
shortened protein of only 480 amino acids is theoretically pro-
duced. The PfRh1/PfRh4 group has two closely-spaced cysteines
around position 270–300. The locations of fusion proteins shown
to bind erythrocytes for PfRh2a/2b, PfRh1 [7,18,19,20,22,25,
26,27,28,29] and PfRh4 are shown [7,18,19,20,22,25,26,27,28,29].
(EPS)
Figure S4 The amino acid sequence of the rRh215 fusion
protein. The location of the recombinant rRh215 fusion protein is
shown underlined in a Figure showing an alignment of the PfRh1,
PfRh4 and PfRh2a/2b proteins beginning at residue numbers
335, 328 and 393 respectively. The alignment is based on a pre-
alignment of cysteine residues as shown in Figure S3. The first
amino acid (Leu, position 500) of the PfRh1 binding domain and
the last amino acid (Asp, position 588) of the PfRh4 binding do-
main is shown.
(EPS)
Figure S5 Purity of the 2b1 and rRh215 fusion proteins used to
bind to erythrocytes in Figure 8. Coomassie stained gels of purified
fusion proteins show that 2b1 migrates at approximately 40 kDa
while rRh215 migrates at approximately 16 kDa on 4–12% SDS-
PAGE gels.
(EPS)
Figure S6 PfRh2a, PfRh2b and PfRh1 recombinant proteins
expressed and purified from E. coli do not bind erythrocytes. (A)
Coomassie-stained gels of purified fusion proteins from PfRh2a
and PfRh2b (19.1 and 45.1) and from PfRh1 (40.1). The 19.1
fusion protein corresponds to amino acids 576–718. The 45.1
fusion protein corresponds to amino acids 297–726. The 40.1
fusion protein corresponds to amino acids 50–833. (B) Purified
fusion proteins detected with anti-His antibodies (left panel) and
following binding and elution from erythrocytes (right panel). Also
shown is binding of rRh215 to red blood cells as a positive control.
(EPS)
Figure S7 Sequence of the codon-optimised PfRh2 binding
domain used to PCR-amplify fragments for three N-terminal fusion
proteinswhichled tothe generationoftheR1070,R1170,1F10and
6F12 antibodies (See Materials And Methods). All fragments were
cloned in the E. coli expression vector, pET45.
(PDF)
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